KRAS and neoplasm: The ATR-Chk1 pathway is required for cell survival in response to oncogenic RAS expression during tumorigenesis and controls tumor progression in a dosage-dependent manner in mouse models24, but how this pathway modulates lung adenocarcinoma (LUAD) phenotypes under KRAS-induced RS is largely unknown.